Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

MAT9001

Other · developed by Matinas Biopharma

Phase 3 Most advanced trial (none active)
MTNB Developer
1 Registered trials

What is MAT9001?

MAT9001 is an investigational drug studied in Severe Hypertriglyceridemia.

At a glance

Drug type
Other
Therapy area
Metabolic
Developer
Matinas Biopharma, Inc (MTNB)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
317SQ4W8IJ

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04662528 Phase 3 Severe Hypertriglyceridemia Withdrawn MTNB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Severe Hypertriglyceridemia

More from Matinas Biopharma

Encochleated Amphotericin B Phase 3 Omega 3 Phase 1/2 Omega 3 pentaenoic acid Phase 2

Follow MTNB, the company behind MAT9001

See MTNB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MTNB catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.